Compounds > ym 529
Page last updated: 2024-09-03

ym 529 and Disease Models, Animal

ym 529 has been researched along with Disease Models, Animal in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aota, Y; Imai, S; Kaneko, K; Saito, T; Taguri, M; Takahashi, M; Tanabe, H; Yamaguchi, Y1
Akagawa, M; Kasukawa, Y; Kawano, T; Miyakoshi, N; Ono, Y; Sato, C; Shimada, Y; Suzuki, M; Tsuchie, H1
Kawabata, K; Kawada, N; Kayasuga, R; Mori, H; Ochi, Y; Tanaka, M; Yamada, H1
Kawabata, K; Mori, H; Tanaka, M1
Kakimoto, S; Mori, M; Nagakura, Y; Okada, M; Sasamata, M; Shibasaki, K; Tamura, S; Tanaka, S; Watabiki, T1
Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H1
Enokida, M; Hagino, H; Okano, T; Teshima, R; Yamane, I; Yamasaki, D1
Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T1
Chatani, Y1
Cui, N; Guo, C; Hashimoto, S; Noma, H; Nomura, T; Okamoto, M; Sato, M; Shibahala, T; Takagi, R; Yokoo, K; Yu, G1
Fushiki, S; Horie, N; Kimura, S; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Nishigaki, Y; Nogawa, M; Segawa, H; Yuasa, T1
Fukata, S; Hagino, H; Kishimoto, Y; Mizumura, H; Tanishima, S; Teshima, R1

Reviews

1 review(s) available for ym 529 and Disease Models, Animal

ArticleYear
[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Clinical calcium, 2005, Volume: 15, Issue:1

    Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Polyisoprenyl Phosphates; Rats; Sesquiterpenes

2005

Other Studies

11 other study(ies) available for ym 529 and Disease Models, Animal

ArticleYear
Minodronate treatment improves low bone mass and reduces progressive thoracic scoliosis in a mouse model of adolescent idiopathic scoliosis.
    PloS one, 2018, Volume: 13, Issue:8

    Topics: Animals; Biomarkers; Bone and Bones; Bone Density; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Mice; Restraint, Physical; Scoliosis; Severity of Illness Index; Treatment Outcome

2018
Analgesic effects of minodronate in a rat chronic pain model.
    Biomedical research (Tokyo, Japan), 2018, Volume: 39, Issue:5

    Topics: Analgesics; Animals; Behavior, Animal; Bone Density; Chronic Pain; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Muscle, Skeletal; Pain Management; Pain Measurement; Rats

2018
Effect of intermittent and daily regimens of minodronic Acid on bone metabolism in an ovariectomized rat model of osteoporosis.
    Calcified tissue international, 2014, Volume: 95, Issue:2

    Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; X-Ray Microtomography

2014
Attenuation of Antiresorptive Action in Withdrawal of Minodronic Acid for Three Months After Treatment for Twelve Months in Ovariectomized Rats.
    Calcified tissue international, 2015, Volume: 97, Issue:4

    Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Inbred F344

2015
Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.
    European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3

    Topics: Acetic Acid; Adenosine Triphosphate; Analgesics, Non-Narcotic; Animals; Bone Density Conservation Agents; CHO Cells; Cricetinae; Cricetulus; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Imidazoles; Injections, Subcutaneous; Male; Mice; Mice, Inbred ICR; Pain; Pain Measurement; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2X2; Receptors, Purinergic P2X3; Time Factors; Transfection

2008
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
    Clinical & experimental metastasis, 2003, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis.
    Arthritis and rheumatism, 2003, Volume: 48, Issue:6

    Topics: Animals; Arthritis, Experimental; Bone Density; Diphosphonates; Disease Models, Animal; Female; Femur; Hindlimb; Imaging, Three-Dimensional; Imidazoles; Joints; Rats; Rats, Sprague-Dawley; Tibia; Tomography, X-Ray

2003
Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models.
    Cancer letters, 2005, Jan-20, Volume: 217, Issue:2

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Diagnostic Imaging; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Luciferases; Luminescent Measurements; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms

2005
Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7

    Topics: Animals; Body Weight; Bone Resorption; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Gene Expression; Glycoproteins; Imaging, Three-Dimensional; Imidazoles; Interleukin-6; Male; Mandible; Membrane Glycoproteins; Mice; Mice, Inbred C3H; Mouth Neoplasms; Neoplasm Invasiveness; Osteoclasts; Osteoprotegerin; Parathyroid Hormone-Related Protein; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha

2005
The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
    Cancer letters, 2006, Jul-08, Volume: 238, Issue:1

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Screening Assays, Antitumor; GTP-Binding Proteins; Imidazoles; Mice; Osteosarcoma

2006
Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.
    Modern rheumatology, 2007, Volume: 17, Issue:3

    Topics: Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley

2007